Lundbeck Foundation is investing a further DKK 15 million in Aarhus-based Insusense Therapeutics, a biotech company which develops new drugs for the treatment of type 2 diabetes and obesity. Insusense Therapeutics originates from research at Aarhus University into a particular family of proteins, sortilins, and their role in diseases of the central nervous system. One...
Read More

About Us

InsuSence Therapeutics is a product-focused biotechnology company based on novel breakthrough science in diabetes biology, which has the potential to quantum leap to important new Type 2 diabetes therapeutics.